Literature DB >> 24947995

Are we there yet? Assessing achievement of vaccine-preventable disease goals in WHO's Western Pacific Region.

Karen Hennessey1, W William Schluter2, Xiaojun Wang2, Liliane Boualam2, Youngmee Jee2, Jorge Mendoza-Aldana2, Sigrun Roesel2, Sergey Diorditsa2, John Ehrenberg2.   

Abstract

Accelerated disease control goals have long been appreciated for their role in galvanizing commitment and bringing a sense of urgency for disease prevention. WHO's Western Pacific Region has 14 on-going communicable disease reduction goals including 1 targeting eradication, 10 targeting elimination, and 3 control initiatives. These goals cover mother-to-child transmission of HIV, congenital syphilis, tuberculosis, leprosy, five parasitic diseases and four vaccine-preventable diseases (VPD). The initiatives have distinct objectives, approaches, and means in which to measure achievement of the goals. Given the long history and experience with VPD initiatives in the Western Pacific Region, this manuscript focuses on the Region's following initiatives: (1) smallpox eradication, (2) polio eradication, (3) measles elimination, (4) maternal and neonatal tetanus elimination (MNTE), and (5) hepatitis B control. There is good consistency across the Region's VPD initiatives yet a pattern of more robust and representative data requirements, stricter evaluation criteria, and more formal evaluation bodies are linked to the intensity of the goal - with eradication being the peak. On the other end of this spectrum, the Regional hepatitis B control initiative has established efficient and low-cost approaches for measuring impact and evaluating if the goals have been met. Even within the confines of VPD initiatives there are some deviations in use of terminology and comparisons across other disease control initiatives in the Region are provided.
Copyright © 2014 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Certification goals; Vaccine-preventable disease

Mesh:

Year:  2014        PMID: 24947995     DOI: 10.1016/j.vaccine.2014.02.093

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Tetanus Immunity among Women Aged 15 to 39 Years in Cambodia: a National Population-Based Serosurvey, 2012.

Authors:  Heather M Scobie; Bunsoth Mao; Sokhal Buth; Kathleen A Wannemuehler; Charlotte Sørensen; Chheng Kannarath; M Harley Jenks; Delynn M Moss; Jeffrey W Priest; Sann Chan Soeung; Michael S Deming; Patrick J Lammie; Christopher J Gregory
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

Review 2.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

3.  Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China.

Authors:  Shigui Yang; Chengbo Yu; Ping Chen; Min Deng; Qing Cao; Yiping Li; Jingjing Ren; Kaijin Xu; Jun Yao; Tiansheng Xie; Chencheng Wang; Yuanxia Cui; Cheng Ding; Guo Tian; Bing Wang; Xiaoyan Zhang; Bing Ruan; Lanjuan Li
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

4.  Study on Status and Willingness towards Hepatitis B Vaccination among Migrant Workers in Chongqing, China: A Cross-Sectional Study.

Authors:  Hui Xiang; Xiaojun Tang; Meng Xiao; Lin Gan; Kun Chu; Shan Li; Yu Tian; Xun Lei
Journal:  Int J Environ Res Public Health       Date:  2019-10-22       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.